We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Photodynamic Therapy, Luminol Used to Kill Cancer cells

By Biotechdaily staff writers
Posted on 02 Aug 2006
Forcing cancer cells to light up could activate light-sensitive drugs that are then able to kill them without damaging nearby healthy tissue, according to recent research.

Researchers based at the College of Judea and Samaria (Ariel) and in association with Bar-Ilan University (Ramat Gan), both in Israel, have for the first time combined two novel techniques to target cancer cells. More...
The first is a form of photodynamic therapy, which delivers a light-sensitive drug specifically to cancer cells. The second technique uses a compound called luminol to generate light inside individual cells, activating the drug and killing the cell. The scientists reported their findings in the July 18, 2006, edition of the British Journal of Cancer.

Photodynamic therapy exploits the properties of specific chemicals that are triggered by normal visible light. In photodynamic therapy, laser light is shone from outside the body to activate chemotherapy drugs. Now it may be possible to use luminol to produce light inside cells, reducing side effects, and enabling the therapy to be used to treat a wider range of tumors.

Lead researcher Dr. Michael Firer, of the department of chemical engineering and Biotechnology at the College of Judea and Samaria, said, "The two big problems with photodynamic therapy are getting the light-sensitive drug to only target cancer cells, and delivering light to the drug to activate it once it is in the right place. We've uniquely combined two cutting-edge technologies to direct a drug to cancer cells and to generate a light source inside the cells. This stops the drug from killing healthy cells. It also means that we might be able to use photodynamic therapy to treat tumors deep inside the body that external light sources cannot reach. We've shown it works in the lab--if it works in real life, we'll have an exciting new way to treat cancer.”

Another unexpected and positive result of using targeted photodynamic therapy was that it removed the drug resistance that develops when untargeted therapies are employed.

Prof. John Toy, medical director of Cancer Research UK, which owns the British Journal of Cancer, remarked, "These are promising results, although there is a long way to go before we can know if this will work in patients. If it does work, it could become a safe, non-invasive option for treating many types of cancers.”



Related Links:
College of Judea and Samaria
Bar-Ilan University

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.